VLA Share Price

Open 0.87 Change Price %
High 0.96 1 Day 0.07 8.05
Low 0.87 1 Week 0.02 2.17
Close 0.94 1 Month -0.16 -14.55
Volume 393226 1 Year -0.08 -7.84
52 Week High 1.35
52 Week Low 0.85
VLA Important Levels
Resistance 2 1.02
Resistance 1 0.99
Pivot 0.92
Support 1 0.89
Support 2 0.86
ASX Australia Most Active Stocks
EHL 0.09 12.50%
EHL 0.09 12.50%
AGO 0.01 0.00%
AGO 0.01 0.00%
AGO 0.01 0.00%
DUE 3.02 1.00%
DUE 3.02 1.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
More..
ASX Australia Top Gainers Stocks
KSO 0.40 3900.00%
HHM 0.02 100.00%
SMD 0.02 100.00%
SMD 0.02 100.00%
ANO 0.03 50.00%
ANO 0.03 50.00%
ANO 0.03 50.00%
IRM 0.03 50.00%
IRM 0.03 50.00%
IRM 0.03 50.00%
More..
ASX Australia Top Losers Stocks
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
TCQ 0.27 -73.53%
GDY 0.01 -50.00%
NGY 0.02 -50.00%
TRM 0.02 -33.33%
TRM 0.02 -33.33%
BYL 0.07 -30.00%
More..

Viralytics Ltd (ASX: VLA)

VLA Technical Analysis 3
As on 23rd Jun 2017 VLA Share Price closed @ 0.94 and we RECOMMEND Sell for LONG-TERM with Stoploss of 1.05 & Sell for SHORT-TERM with Stoploss of 1.06 we also expect STOCK to react on Following IMPORTANT LEVELS.
VLA Target for June
1st Target up-side 1.15
2nd Target up-side 1.19
3rd Target up-side 1.23
1st Target down-side 1.05
2nd Target down-side 1.01
3rd Target down-side 0.97
VLA Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.viralytics.com
VLA Address
VLA
66 Hunter Street
Suite 305
Sydney, NSW 2000
Australia
Phone: 61 2 9988 4000
Fax: 61 2 8068 6038
Interactive Technical Analysis Chart Viralytics Ltd ( VLA ASX Australia )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Viralytics Ltd
VLA Business Profile
Viralytics Limited, a biotechnology company, develops oncolytic virotherapy for the treatment of a range of cancers primarily in Australia. The company primarily develops CAVATAK, a Phase II clinical trial product for the treatment of late stage melanoma; has completed a Phase I single dose-escalation intravenous study for the treatment of melanoma, breast, prostate, and colon cancers; and has completed a multi dose intratumoral trial for the treatment of late stage head and neck cancers. It also develops EVATAK, which is in a preclinical stage for the treatment of gastric and ovarian cancers. The company was formerly known as Psiron Ltd. and changed its name to Viralytics Limited in December 2006. Viralytics Limited is headquartered in Sydney, Australia.